ENTRADA THERAPEUTICS, INC. Capital Expenditures
ENTRADA THERAPEUTICS, INC. (TRDA) reported Capital Expenditures of $55.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $11.00K, a 96.00% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $44.00K, a 96.15% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was -$207.00K, a 132.60% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was -$171.00K, a 126.76% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $1.04M, a 67.04% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $3.16M, a 43.75% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $5.61M, a 94.46% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $2.89M, a 36.97% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $55.00K 10-Q · filed 2026-08-05 | -$152.00K derived: sum of 3 quarters · filed 2026-08-05 | -$323.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-07 | -$163.00K derived: sum of 2 quarters · filed 2026-05-07 | -$334.00K derived: sum of 3 quarters · filed 2026-05-07 | -$59.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$378.00K derived: sum of 2 quarters · filed 2026-02-26 | -$103.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $104.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.25M 10-Q · filed 2025-11-06 | $1.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.42M 10-Q · filed 2026-08-05 | $2.05M derived: sum of 3 quarters · filed 2026-08-05 | $2.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.14M 10-Q · filed 2026-05-07 | $1.78M derived: sum of 2 quarters · filed 2026-05-07 | $2.42M derived: sum of 3 quarters · filed 2026-05-07 | $3.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.27M derived: sum of 2 quarters · filed 2026-02-26 | $2.32M derived: sum of 3 quarters · filed 2026-02-26 | $3.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $639.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.69M derived: sum of 2 quarters · filed 2025-11-06 | $2.52M 10-Q · filed 2025-11-06 | $3.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.88M 10-Q · filed 2025-08-06 | $2.86M derived: sum of 3 quarters · filed 2025-08-06 | $4.31M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $838.00K 10-Q · filed 2025-05-08 | $1.81M derived: sum of 2 quarters · filed 2025-05-08 | $3.26M derived: sum of 3 quarters · filed 2025-05-08 | $4.78M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $976.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.42M derived: sum of 2 quarters · filed 2025-02-27 | $3.95M derived: sum of 3 quarters · filed 2025-02-27 | $5.61M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $2.97M derived: sum of 2 quarters · filed 2024-11-05 | $4.64M 10-Q · filed 2024-11-05 | $5.35M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.19M 10-Q · filed 2024-08-13 | $3.90M derived: sum of 3 quarters · filed 2024-08-13 | $4.71M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-07 | $2.38M derived: sum of 2 quarters · filed 2024-05-07 | $3.19M derived: sum of 3 quarters · filed 2024-05-07 | $3.96M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $708.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.52M derived: sum of 2 quarters · filed 2024-03-13 | $2.29M derived: sum of 3 quarters · filed 2024-03-13 | $2.89M 10-K · filed 2024-03-13 |
| 2022-09-30 | $810.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.58M derived: sum of 2 quarters · filed 2023-11-07 | $2.18M 10-Q · filed 2023-11-07 | $3.50M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $775.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.37M 10-Q · filed 2023-08-08 | $2.69M derived: sum of 3 quarters · filed 2023-08-08 | $3.50M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $594.00K 10-Q · filed 2023-05-10 | $1.92M derived: sum of 2 quarters · filed 2023-05-10 | $2.72M derived: sum of 3 quarters · filed 2023-05-10 | $4.27M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.13M derived: sum of 2 quarters · filed 2023-03-06 | $3.67M derived: sum of 3 quarters · filed 2023-03-06 | $4.58M 10-K · filed 2023-03-06 |
| 2021-09-30 | $806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.35M derived: sum of 2 quarters · filed 2022-11-07 | $3.26M 10-Q · filed 2022-11-07 | $4.70M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.45M 10-Q · filed 2022-08-11 | $3.90M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $908.00K 10-Q · filed 2022-05-12 | $2.35M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.32M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $874.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |